Background: There is consensus that dementia is the most burdensome disease for modern societies. Few cost-of-illness studies examined the complexity of Alzheimer's disease (AD) burden, considering at the same time health and social care, cash allowances, informal care, and out-of-pocket expenditure by families. Methods: This is a comprehensive cost-of-illness study based on the baseline data from a randomized controlled trial (UP-TECH) enrolling 438 patients with moderate AD and their primary caregiver living in the community. Results: The societal burden of AD, composed of public, patient, and informal care costs, was about �20,000/yr. Out of this, the cost borne by the public sector was �4,534/yr. The main driver of public cost was the national cash-for-care allowance (�2,324/yr), followed by drug prescriptions (�1,402/yr). Out-of-pocket expenditure predominantly concerned the cost of private care workers. The value of informal care peaked at �13,590/yr. Socioeconomic factors do not influence AD public cost, but do affect the level of out-of-pocket expenditure. Conclusion: The burden of AD reflects the structure of Italian welfare. The families predominantly manage AD patients. The public expenditure is mostly for drugs and cash-for-care benefits. From a State perspective in the short term, the advantage of these care arrangements is clear, compared to the cost of residential care. However, if caregivers are not adequately supported, savings may be soon offset by higher risk of caregiver morbidity and mortality produced by high burden and stress. The study has been registered on the website www.clinicaltrials.org (Trial Registration number: NCT01700556). Copyright � International Psychogeriatric Association 2015.

The economic impact of moderate stage Alzheimer's disease in Italy: Evidence from the UP-TECH randomized trial / Chiatti, C.; Furneri, G.; Rimland, J. M.; Demma, F.; Bonfranceschi, F.; Cassetta, L.; Masera, F. b; Cherubini; Corsonello, A.; Lattanzio, F.; Baldassarri, D.; Bitti, L.; Carosi, A.; Sabbatini, M.; Paolasini, E.; Fiori, T.; Fronzi, C.; Giacchetta, S.; Giacomini, V.; Giovagnoli, L.; Lattanzi, G.; Manca, A. M.; Marinelli, I.; Pigini, V.; Pignotti, M.; Proietti, M. C.; Quarticelli, A.; Rovedi, M.; Tasso, L.; Valeri, V.; Antonioli, A.; Barabucci, M.; Bassani, M.; Bollettini, P.; Bruttapasta, M. C.; Buccolini, C.; Carangella, R.; Carboni, F.; Ceccolini, D.; D'Incecco, P.; Di Felice, M.; Dini, L.; Gioia, G.; Di Prima, G.; Giusepponi, G.; Lanciotti, C.; Loffreda, A.; Luciani, O.; Mariani, L.; Mastrorilli, F.; Moroni, R.; Piatkowska, I.; Rucoli, R.; Scoccia, G.; Teodori, N.; Tonelli, T.; Angeloni, R.; Bratti, R. A.; Bonafede, G.; Lorenzetti, S.; Paci, C.; Picciotti, G.; Pezzola, D.; Rea, V.; Scialè, V.; Signorino, M.; Sorvillo, F.; Tomassini, P. F.; Ciccola, A.; Cionfrini, L.; Alessandrini, D.; De Santis, A.; Formica, B.; Tacchi, G.; Tortorelli, S.; Marchegiani, G.; Pozzari, G.; Santarelli, G.; Bartolucci, D.; Caraffa, G.; CAVALLO, Filippo; Di Furia, L.; Lacetera, A.; Maffei, C. M.; Manzoli, L.; Postacchini, D.; Bevilacqua, R.; Bonfigli, A. R.; Bustacchini, S.; Capasso, M.; Civerchia, P.; Di Rosa, M.; Giuli, C.; Marcellini, M.; Marinelli, P.; Melchiorre, G.; Moraca, M. E.; Principi, A.; Rocchetti, C.; Spazzafumo, L.; Vincitorio, D.; Bartulewicz, K.; Olivetti, P.; Rossi, L.. - In: INTERNATIONAL PSYCHOGERIATRICS. - ISSN 1041-6102. - STAMPA. - 27:(2015), pp. 1563-1572. [10.1017/S104161021500040X]

The economic impact of moderate stage Alzheimer's disease in Italy: Evidence from the UP-TECH randomized trial

CAVALLO, Filippo;
2015

Abstract

Background: There is consensus that dementia is the most burdensome disease for modern societies. Few cost-of-illness studies examined the complexity of Alzheimer's disease (AD) burden, considering at the same time health and social care, cash allowances, informal care, and out-of-pocket expenditure by families. Methods: This is a comprehensive cost-of-illness study based on the baseline data from a randomized controlled trial (UP-TECH) enrolling 438 patients with moderate AD and their primary caregiver living in the community. Results: The societal burden of AD, composed of public, patient, and informal care costs, was about �20,000/yr. Out of this, the cost borne by the public sector was �4,534/yr. The main driver of public cost was the national cash-for-care allowance (�2,324/yr), followed by drug prescriptions (�1,402/yr). Out-of-pocket expenditure predominantly concerned the cost of private care workers. The value of informal care peaked at �13,590/yr. Socioeconomic factors do not influence AD public cost, but do affect the level of out-of-pocket expenditure. Conclusion: The burden of AD reflects the structure of Italian welfare. The families predominantly manage AD patients. The public expenditure is mostly for drugs and cash-for-care benefits. From a State perspective in the short term, the advantage of these care arrangements is clear, compared to the cost of residential care. However, if caregivers are not adequately supported, savings may be soon offset by higher risk of caregiver morbidity and mortality produced by high burden and stress. The study has been registered on the website www.clinicaltrials.org (Trial Registration number: NCT01700556). Copyright � International Psychogeriatric Association 2015.
2015
27
1563
1572
Chiatti, C.; Furneri, G.; Rimland, J. M.; Demma, F.; Bonfranceschi, F.; Cassetta, L.; Masera, F. b; Cherubini; Corsonello, A.; Lattanzio, F.; Baldassa...espandi
File in questo prodotto:
File Dimensione Formato  
chiatti2015.pdf

Accesso chiuso

Dimensione 217.27 kB
Formato Adobe PDF
217.27 kB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1210764
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 19
  • ???jsp.display-item.citation.isi??? 19
social impact